RE:Confirming ability to destroy metastasis will be a majorGreat post, Bencro. Concise and clear... and no mention of he who must not be named.... or his sidekick
bencro wrote: As per Dr. Kulkarni's statement, this clinical trial is about adjuvant. It will come in support of what scrapping has not been able to remove at microscopic levels and why NMIBC has such high recurence frequency.
So if no tumour re-growth at 3-months, 6-months, etc ..., it will confirm TLT's technology ability to destroy metastasis that are behind tumour recurences and spreading of cancers to other organs. This is gonna be big and it will make our technology an incontournable to use before any last resort treatment (cystectomy in the case of NMIBC).
Sales will then be at the rendez-vous right year one.
And over time, they will do other trials to make it a stand alone treatment, as per Dr. Jewett statement. Normal gradual process.
Same gradual pattern as seen with Keytruda lung cancer. First used an adjuvant and then, data confirm over time the edge over chemo. Then FDA give first-line treatment to Keytruda over chemo.
So 25% market shares are fair to assume, as per TLT's urology MSAB assessment. Roger is not working alone when coming up with these numbers.